COVID-19 treatment: BioCryst begins Clinical Trial with Galidesivir
by Press Release from Outbreak News Today on (#522AF)
BioCryst Pharmaceuticals, Inc. announced last week that the company has opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. Galidesivir is an investigational broad-spectrum antiviral drug that was safe and well tolerated in previously reported Phase 1 trials in healthy ["]
The post COVID-19 treatment: BioCryst begins Clinical Trial with Galidesivir appeared first on Outbreak News Today.